Dr Cecile Yelnik presenting at #ACR23 on Behalf of APS_ACTION - Antiphospholipid Syndrome (#APS) & Complement Pathway Activation acrabstracts.org/abstract/compl….

Dr Alexander Pine Presenting at #ACR23 - APS_ACTION & Yale School of Medicine Collaboration on Antiphospholipid Syndrome and Plasma Proteomic Profiling acrabstracts.org/abstract/plasm…

APS_ACTION Core Laboratories Presented at #ACR23 Their Performance Assessment of LA Testing Using TSVT/ECT. acrabstracts.org/abstract/perfo….

Today we have award-winning #APS researcher Doruk Erkan with us, who explains the importance of creating new classification criteria for APS & what the proper use of them ought to be! Listen → acronair.org #ACR23

Antiphospholipid Syndrome Diagnosis versus Classification. What is the Difference? The answer is in this recently updated Hospital for Special Surgery (HSS) Top 10 Series Patient Web Article hss.edu/conditions_top…

ICYMI: In this #RPTH Commentary Mark Crowther and Doruk Erkan discuss the new ACR/EULAR 2023 #Antiphospholipid Syndrome classification and how it may be applied across different clinical scenarios! Read here➡️: rpthjournal.org/article/S2475-…

#ACR23 Recap: @dorukerkanmd and Jason S Knight explained the antiphospholipid syndrome classification criteria developed by the ACR and EULAR. Read more in ACR Convergence Today → acr.tw/3N6aY5v

Our most recent publication on thrombosis recurrence and major bleeding risk in non-anticoagulated thrombotic antiphospholipid syndrome patients. We want to thank all APS ACTION members for their contributions. pubmed.ncbi.nlm.nih.gov/38185079/

🤔🩸🔮 Rethinking antiphospholipid syndrome to guide future management and research NatRevRheumatol Doruk Erkan nature.com/articles/s4158…

HSS investigators presented new research findings in #antiphospholipidsyndrome at the American College of Rheumatology Convergence 2024 meeting. #ACR24 #HSSRhem Doruk Erkan APS_ACTION news.hss.edu/new-antiphosph…

Damage Index for Antiphospholipid Syndrome (DIAPS): An Antiphospholipid Syndrome Alliance for Clinical Trials and I… pubmed.ncbi.nlm.nih.gov/39662300/

ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the APS ACTION Clinical … pubmed.ncbi.nlm.nih.gov/39423147/

Thrombosis recurrence and major bleeding in non-anticoagulated thrombotic antiphospholipid syndrome patients: Prosp… pubmed.ncbi.nlm.nih.gov/38185079/

2023 American College of Rheumatology/European League Against Rheumatism antiphospholipid syndrome classification c… pubmed.ncbi.nlm.nih.gov/39395544/

Survey Reveals 60% Satisfaction with DIAPS but Highlights Need for Improvements: cutt.ly/ge3C9xa4 APS_ACTION Doruk Erkan

Predictors of Mortality in Antiphospholipid Antibody Positive Patients: Prospective Results from APS ACTION. pubmed.ncbi.nlm.nih.gov/39895040/

Most Recent APS ACTION Publication: pubmed.ncbi.nlm.nih.gov/40737058/

Congratulations to 2025 APSACTION Silvia Pierangeli Young Scholar Award (in collaboration with APS Foundation of America) Recipients: Alice Barinotti, Zeynep Erton, Alex Luta, Liala Moschetti, Andrew Song. During #ICAPA25, Alice and Zeynep received their certificates in person.

APS_ACTION Scientific Session and Poster Presentations During #ICAPA25 (18th International Congress on Antiphospholipid Antibodies, Kyoto, Japan). Thank you to all the presenters and session participants.

APS_ACTION 2025 Young Scholar Zeynep Belce Erton from Hospital for Special Surgery (HSS) Presenting her Research During #ICAPA25 (18th International Congress on Antiphospholipid Antibodies, Kyoto, Japan).